Understanding Financial Distress in Patients with Advanced Cancer
the Cancer Therapy Advisor take:
More than 30% of patients with advanced cancer (AdCa) reported more severe financial distress (FD) than physical, family, and emotional distress, according to an article published online in the journal The Oncologist.
In total, 149 patients were interviewed: 77 of which were at a comprehensive cancer center (CCC) and 72 of which were at a general public hospital (GPH). The median age of participants was 60 years (95% CI: 58.6, 61.5 years). Of the 149 participants, 74 (50%) were females.
Forty-eight (62%) of the 77 patients at a CCC and 13 out of 72 (18%) patients at a GPH were white, while 21 of 77 (27%) patients at CCC and 32 of 72 (38%) at GPH were black; and 7 of 77 (9%) versus 27 of 72 (38%) at CCC and GPH, respectively, were Hispanic (P<0.0001).
Results showed 65 out of 75 patients at CCC reported having FD (86%; 95% CI: 76%, 93%) compared to 65 out of 72 at GPH (90%; 95% CI: 81%, 96%; P=0.45).
AdCa reported suffering from more severe FD compared to physical distress (45 patients; 30%), distress concerning physical functioning (46 patients; 31%), social/family distress (64 patients; 43%), and emotional distress (55 patients; 37%) –all of which were significantly worse for patients at GPH; P<0.05.
Furthermore, the median score reported by AdCa regarding how much their FD was affecting their general well-being was 5 (IQR: 1-8).
More than 30% of patients with advanced cancer reported more severe financial distress than physical, family, and emotional distress.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Ginkgo Biloba and Cancer
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC
- Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- FDA Grants Breakthrough Therapy Designation to Adjuvant Dabrafenib Plus Trametinib for Melanoma
- Long-term Eltrombopag Improves Outcomes in Chronic Immune Thrombocytopenia
- Phase 1 Trial of Guadecitabine With Vaccine and Cyclophosphamide for Metastatic Colorectal Cancer
- Success of Adoptive Cell Therapy in ALL Could Be Applied to Myeloma
- Curative-intent Surgery for Cancer Increases Risk of New Persistent Opioid-use